Systems-level hematopoietic and immune cells

Systems-level hematopoietic and immune cells refers to the complex, interconnected network of cells responsible for blood production and immune surveillance. This system originates from hematopoietic stem cells (HSCs) in the bone marrow, which differentiate into myeloid and lymphoid lineages to provide both innate and adaptive immunity (Jagannathan-Bogdan & Zon, 2013, Blood). Rather than representing a single molecular target, this term describes a biological system that is increasingly analyzed using high-throughput "omics" technologies to understand cell-state transitions and signaling networks (Schultze, 2015, Science). Pathological states involving this system include hematologic malignancies like leukemia, where normal differentiation is disrupted, and autoimmune diseases where immune tolerance is lost (Abbas et al., 2018, Cellular and Molecular Immunology). While specific proteins within these cells, such as CD20 or JAK kinases, are valid therapeutic targets, the system as a whole serves as the physiological environment for drug action. Consequently, drugs interacting with this system often aim to either suppress overactive immune responses or stimulate the production of specific cell populations (Janeway et al., 2001, Immunobiology). Understanding the systems-level interactions is critical for predicting drug efficacy and managing systemic toxicities like myelosuppression or cytokine release syndrome.

Other names

Hematopoietic systemImmune systemBlood and immune cell networkHematopoietic lineage

Therapeutic intervention involves immunomodulation, stimulation of hematopoietic progenitor cells, or targeted depletion of specific immune cell subsets to restore physiological balance.